Keyword: Tecfidera

MyHealthTeams specialized social networks are adding pharma-sponsored resource centers with its most recent in spondyloarthritis.

Biogen grew sales 9% in the second quarter, beating Street expectations, but analysts on the company's conference call were focused elsewhere.

A patent ruling for Novartis will give Celgene time to secure FDA approval for its Gilenya rival and persuade physicians that it's a safer MS pill.

NICE is now endorsing Ocrevus for NHS coverage in relapsing-remitting MS and will deliver a decision on the primary progressive form soon.

Top drugmakers made more trips to the courthouse last year, aiming to blockade big-selling drugs against generic competitors.

Roche says it's in the midst of one of the most successful multiple sclerosis launches ever—and MS has had some doozies.

Celgene's MS candidate ozanimod might have challenged some big blockbusters in the field, but an FDA decision means it won't happen anytime soon.

Biogen boosted the stickers on some of its key MS medications Monday, and the payoff could make up for sales lost to new rivals.

In just a few years, pharma's top launches of 2014 have amassed huge sales and reshaped treatment—and they're now among the biggest launches ever.

Merck KGaA has won European approval for its oral MS drug, but competing with more established rivals won't be easy.